GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 10, 2005, Pages 1315-1331

  Kypta, Robert M ^a,b  

^a CIC BIOGUNE   (Spain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Glycogen synthase kinase 3 (GSK 3) inhibitor

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 [2 (2,6 DIMETHOXYPHENYL)MORPHOLIN 4 YL] 3 METHYL 6 (PYRIMIDIN 4 YL) 3H PYRIMIDIN 4 ONE; 2 HYDROXY 3 [4[(4 METHYLPIPERAZIN 1 YL)CARBONYL]PYRIDIN 2YL] 1H INDOLE 5 CARBONITRILE; 3 (1,2,3,4 TETRAHYDRO[1,4]DIAZEPINO[6,7,1 HI]INDOL 7 YL) 4 (5 FLUOROBENZOFURAN 7 YL) 2,5 DIOXOPYRROLE; 3 BROMO 5 PHENYL 1H PYRAZOLO[3,4 B]PYRIDINE; 4 (2,1,3 BENZOXADIAZOL 4 YL) 5 CYANO 4,7 DIHYDRO 6 (1 METHYLPIPERIDIN 4 YL) 2H PYRAZOLO[3,4 B]PYRIDINE; 5 METHYL 4 OXO 6 PHENYL 3,4 DIHYDROPYRROLO[3,2 D]PYRIMIDINE 7 CARBONITRILE; 7,7 DIMETHYL 9 (2 METHYL 6,7 DIHYDRO 5H CYCLOPENTAL[B]PYRIDIN 6 YLMETHYL) 2 (PYRIDIN 4 YL) 6,7,8,9 TETRAHYDRO PYRIMIDO[1,2 A]PYRIMIDIN 4 ONE; ALSTERPAULLONE; AMINOPYRIDINE DERIVATIVE; ANILINOARYLMALEIMIDE; AR AO 14418; BISINDOLYLMALEIMIDE; CARBAZOLE DERIVATIVE; CHIR 025; CHIR 98014; CHIR 99021; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDOLE DERIVATIVE; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; N (4 METHOXYBENZYL) N' (5 NITRO 1,3 THIAZOL 2 YL)UREA; N [6 (4 CHLOROPHENYL) 1H PYRAZOLO[3,4 B] PYRIDIN 3 YL]ACETAMIDE; PAULLONE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; ROSCOVITINE; TWS 119; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CANCER; DRUG STRUCTURE; DRUG TARGETING; ENZYME INDUCTION; HUMAN; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW;

EID: 27744574179     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.10.1315     Document Type: Review

References (77)

1. DOBLE BW, WOODGETT JR: GSK3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. (2003) 116(Pt.7):1175-1186.
2. LUCAS JJ, HERNANDEZ F, GOMEZ-RAMOS P et al.: Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. (2001) 20(1-2):27-39.
3. HERNANDEZ F, BORRELL J, GUAZA C, AVILA J, LUCAS JJ: Spatial learning deficit in transgenic mice that conditionally overexpress GSK-3β in the brain but do not form tau filaments. J. Neurochem. (2002) 83(6):1529-1533.
4. ANNAERT W, DE STROOPER B: A cell biological perspective on Alzheimer's disease. Annu. Rev. Cell Dev. Biol. (2002) 18:25-51.
5. BHAT RV, BUDD HAEBERLEIN SL, AVILA J: Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. (2004) 89(6):1313-1317.
6. PEREZ M, HERNANDEZ F, LIM F, DIAZ-NIDO J, AVILA J: Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. (2003) 5(4):301-308.
7. NOBLE W, PLANEL E, ZEHR C et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA (2005) 102(19):6990-6995.
8. SANTACRUZ K, LEWIS J, SPIRES T et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 309(5733):476-481.
9. SUN X, SATO S, MURAYAMA O et al.: Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. (2002) 321(1-2):61-64.
10. PHIEL CJ, WILSON CA, LEE VM, KLEIN PS: GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature (2003) 423(6938):435-439.
11. LEE MS, KAO SC, LEMERE CA et al.: APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. (2003) 163(1):83-95.
12. RYDER J, SU Y, LIU F et al.: Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. (2003) 312(4):922-929.
13. SU Y, RYDER J, LI B et al.: Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry (2004) 43(22):6899-6908.
14. BAKI L, SHIOI J, WEN P et al.: PS1 activates PI3K thus inhibiting GSK3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. (2004) 23(13):2586-2596.
15. TAKASHIMA A, MURAYAMA M, MURAYAMA O et al.: Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc. Natl. Acad. Sci. USA (1998) 95(16):9637-9641.
16. RYDER J, SU Y,NI B: Akt/GSK3β serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell. Signal. (2004) 16(2):187-200.
17. MEIJER L, FLAJOLET M, GREENGARD P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. (2004) 25(9):471-480.
18. COHEN P, GOEDERT M: GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. (2004) 3(6):479-487.
19. WAGMAN AS, JOHNSON KW, BUSSIERE DE: Discovery and development of GSK3 inhibitors for the treatment of Type 2 diabetes. Curr. Pharm. Des. (2004) 10(10):1105-1137.
20. COGHLAN MP, CULBERT AA, CROSS DA et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7(10):793-803.
21. CROSS DA, CULBERT AA, CHALMERS KA et al.: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. (2001) 77(1):94-102.
22. FACCI L, STEVENS DA, SKAPER SD: Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 14(11):1467-1470.
23. BERTRAND JA, THIEFFINE S, VULPETTI A et al.: Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. (2003) 333(2):393-407.
24. SMITH DG, BUFFET M, FENWICK AE et al.: 3-Amino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2001) 11(5):635-639.
25. ENGLER TA, HENRY JR, MALHOTRA S et al.: Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tenahydro-[1,4]diazepino-[6,7, 1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J. Med. Chem. (2004) 47(16):3934-3937.
26. ENGLER TA, MALHOTRA S, BURKHOLDER TP et al.: The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(4):899-903.
27. ZHANG HC, WHITE KB, YE H et al.: Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. (2003) 13(18):3049-3053.
28. HERS I, TAVARE JM, DENTON RM: The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. (1999) 460(3):433-436.
29. KUO GH, PROUTY C, DEANGELIS A et al.: Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3β inhibitors. J. Med. Chem. (2003) 46(19):4021-4031.
30. SHEN L, PROUTY C, CONWAY BR et al.: Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors. Bioorg. Med. Chem. (2004) 12(5):1239-1255.
31. ZHANG HC, YE H, CONWAY BR et al.: 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. (2004) 14(12):3245-3250.
32. O'NEILL DJ, SHEN L, PROUTY C et al.: Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors. Bioorg. Med. Chem. (2004) 12(12):3167-3185.
33. RING DB, JOHNSON KW, HENRIKSEN EJ et al.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes (2003) 52(3):588-595.
34. KELLY S, ZHAO H, HUA SUN G et al.: Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp. Neurol. (2004) 188(2):378-386.
35. PEAT AJ, BOUCHERON JA, DICKERSON SH et al.: Novel pyrazolopyrimidine derivatives as GSK3 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(9):2121-2125.
36. PEAT AJ, GARRIDO D, BOUCHERON JA et al.: Novel GSK3 inhibitors with improved cellular activity. Bioorg. Med. Chem. Lett. (2004) 14(9):2127-2130.
37. MAEDA Y, NAKANO M, SATO H et al.: 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(15):3907-3911.
38. DING S, WU TY, BRINKER A et al.: Synthetic small molecules that control stem cell fate. Proc. Natl Acad. Sci. USA (2003) 100(13):7632-7637.
39. WITHERINGTON J, BORDAS V, GAIBA A et al.: 6-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(18):3055-3057.
40. WITHERINGTON J, BORDAS V, GAIBA A et al.: 6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(18):3059-3062.
41. WITHERINGTON J, BORDAS V, GARLAND SL et al.: 5-aryl-pyrazolo[3,4-blpyridines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(9):1577-1580.
42. WITHERINGTON J, BORDAS V, HAIGH D et al.: 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(9):1581-1584.
43. TAVARES FX, BOUCHERON JA, DICKERSON SH et al.: N-Phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J. Med. Chem. (2004) 47(19):4716-4730.
44. BHAT R, XUE Y, BERG S et al.: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. (2003) 278(46):45937-45945.
45. GOULD TD, EINAT H, BHAT R, MANJI HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. (2004) 7(4):387-390.
46. OLESEN PH, SORENSEN AR, URSO B et al.: Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl- 1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK3 inhibitors. J. Med. Chem. (2003) 46(15):3333-3341.
47. LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. (2001) 276(1):251-260.
48. MEIJER L, SKALTSOUNIS AL, MAGIATIS P et al.: GSK3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. (2003) 10(12):1255-1266.
49. POLYCHRONOPOULOS P, MAGIATIS P, SKALTSOUNIS AL et al.: Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. (2004) 47(4):935-946.
50. LEOST M, SCHULTZ C, LINK A et al.: Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. (2000) 267(19):5983-5994.
51. KNOCKAERT M, WIEKING K, SCHMITT S et al.: Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. (2002) 277(28):25493-25501.
52. KUNICK C, LAUENROTH K, LEOST M, MEIJER L, LEMCKE T: 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β. Bioorg. Med. Chem. Lett. (2004) 14(2):413-416.
53. METTEY Y, GOMPEL M, THOMAS V et al.: Aloisines, a new family of CDK/GSK3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. (2003) 46(2):222-236.
54. NAERUM L, NORSKOV-LAURITSEN L, OLESEN PH: Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(11):1525-1528.
55. MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. (2000) 7(1):51-63.
56. MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. (2002) 45(6):1292-1299.
57. LUNA-MEDINA R, CORTES-CANTELI M, ALONSO M et al.: Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation. J. Biol. Chem. (2005) 280(22):21453-21462.
58. CONDE S, PEREZ DI, MARTINEZ A, PEREZ C, MORENO FJ: Thienyl and phenyl α-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3β) from a library of compound searching. J. Med. Chem. (2003) 46(22):4631-4633.
59. THOMAS GM, FRAME S, GOEDERT M et al.: A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and β-catenin. FEBS Lett. (1999) 458(2):247-251.
60. CULBERT AA, BROWN MJ, FRAME S et al.: GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett. (2001) 507(3):288-294.
61. LI B, RYDER J, SU Y et al.: FRAT1 peptide decreases Aβ production in swAPP(751) cells. FEBS Lett. (2003) 553(3):347-350.
62. HEDGEPETH CM, DEARDORFF MA, RANKIN K, KLEIN PS: Regulation of glycogen synthase kinase 3β and downstream Wnt signaling by axin. Mol. Cell. Biol. (1999) 19(10):7147-7157.
63. FUJIMURO M, WU FY, APRHYS C et al.: A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. (2003) 9(3):300-306.
64. PLOTKIN B, KAIDANOVICH O, TALIOR I, ELDAR-FINKELMAN H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. (2003) 305(3):974-980.
65. KAIDANOVICH-BEILIN O, MILMAN A, WEIZMAN A, PICK CG, ELDAR-FINKELMAN H: Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biol. Psychiatry (2004) 55(8):781-784.
66. YU JY, TAYLOR J, DERUITER SL, VOJTEK AB, TURNER DL: Simultaneous inhibition of GSK-3α and GSK-3β using hairpin siRNA expression vectors. Mol. Ther. (2003) 7(2):228-236.
67. STANKUNAS K, BAYLE JH, GESTWICKI JE et al.: Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol. Cell (2003) 12(6):1615-1624.
68. HOEFLICH KP, LUO J, RUBIE EA et al.: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature (2000) 406(6791):86-90.
69. O'BRIEN WT, HARPER AD, JOVE F et al.: Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. (2004) 24(30):6791-6798.
70. MOON RT, KOHN AD, DE FERRARI GV, KAYKAS A: WNT and β-catenin signalling: diseases and therapies. Nat. Rev. Genet. (2004) 5(9):691-701.
71. FUENTEALBA RA, FARIAS G, SCHEU J et al.: Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer's disease. Brain Res. Brain Res. Rev. (2004) 47(1-3):275-289.
72. DE CRAENE B, VAN ROY F, BERX G: Unraveling signalling cascades for the Snail family of transcription factors. Cell. Signal. (2005) 17(5):535-547.
73. SCHLESSINGER K, HALL A: GSK-3β sets Snail's pace. Nat. Cell Biol. (2004) 6(10):913-915.
74. COHEN Y, CHETRIT A, COHEN Y, SIROTA P, MODAN B: Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. (1998) 15(1):32-36.
75. MAZOR M, KAWANO Y, ZHU H, WAXMAN J, KYPTA RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene (2004) 23(47):7882-7892.
76. OUGOLKOV AV, FERNANDEZ-ZAPICO ME, SAVOY DN, URRUTIA RA, BILLADEAU DD: Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. (2005) 65(6):2076-2081.
77. SHAKOORI A, OUGOLKOV A, YU ZW et al.: Deregulated GSK-3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. (2005) 334(4):1365-1373.